Pharmaceutical

HTA outcomes in the 5EU are growing at 27% with a deep commitment to oncology

GlobalData has analysed HTA decisions made for branded medicines in 5EU from 2018 to 2022, with a focus on oncology.

Jul 13, 2023 - 20:00
HTA outcomes in the 5EU are growing at 27% with a deep commitment to oncology
GlobalData has analysed HTA decisions made for branded medicines in 5EU from 2018 to 2022, with a focus on oncology.
Read the original article

Tags:

Previous Article

Atrial fibrillation market set to decline at a CAGR of 1.3% between 2022 and 2032

Next Article

Roche eyes alternate mode of administration for Ocrevus in MS

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Nobel Prize, in a rarity, celebrates a fruitful and durable partnership

STAT+: Nobel Prize, in a rarity, celebrates a fruitful ...

Oct 2, 2023

Harnessing the untapped potential of medicines access 

Harnessing the untapped potential of medicines access 

Jan 25, 2024

Risk adjusted net present value: What is the current va...

Apr 17, 2024